Table 1 Baseline characteristics of the patients and the associations between patient characteristics and ANCA status at switching to maintenance therapy. p refers to the difference between the ANCA +ve and ANCA-ve status at switch to maintenance therapy.
All patients | ANCA –ve | ANCA + ve | p | |
|---|---|---|---|---|
n (%) | 252 | 141 (56%) | 111 (44%) | 0.36 |
Male Female | 158 94 | 92 49 | 66 45 | |
Age (years) | 59 (47–67) | 62 (50–68) | 54 (42–66) | 0.009 |
Creatinine at entry (μmol/L) | 177 (108–239) | 185 (126–327) | 151 (97–258) | 0.007 |
Creatinine strata (μmol/L) | 0.077 | |||
< 100 101–200 > 200 | 54 90 108 | 24 49 68 | 30 41 40 | |
ANCA specificity at entry | 0.7 | |||
MPO PR3 | 107 145 | 58 83 | 49 62 | |
Diagnosis | 0.45 | |||
MPA GPA | 118 134 | 63 78 | 55 56 | |
Time to remission (months) | 3 (2.7–4.1) | 3 (2–3.7) | 3.2 (3–4.5) | 0.001 |
Cyclophosphamide | 0.53 | |||
Continuous Pulse | 117 135 | 68 73 | 49 62 | |
Maintenance therapy | 0.093 | |||
AZA MMF Other | 175 73 4 | 103 34 4 | 72 39 0 | |
Relapse:no-relapse | 102:150 | 47:94 | 55:56 | 0.025 |